Design Therapeutics/$DSGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Design Therapeutics
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Ticker
$DSGN
Sector
Primary listing
Employees
54
Headquarters
Website
DSGN Metrics
BasicAdvanced
$636M
-
-$1.22
1.63
-
Price and volume
Market cap
$636M
Beta
1.63
52-week high
$11.23
52-week low
$2.60
Average daily volume
248K
Financial strength
Current ratio
17.142
Quick ratio
16.968
Long term debt to equity
0.304
Total debt to equity
0.722
Profitability
EBITDA (TTM)
-78.445
Management effectiveness
Return on assets (TTM)
-20.66%
Return on equity (TTM)
-30.70%
Valuation
Price to book
2.93
Price to tangible book (TTM)
2.93
Price to free cash flow (TTM)
-10.835
Free cash flow yield (TTM)
-9.23%
Free cash flow per share (TTM)
-0.952
Growth
Earnings per share change (TTM)
38.92%
3-year earnings per share growth (CAGR)
2.32%
What the Analysts think about DSGN
Analyst ratings (Buy, Hold, Sell) for Design Therapeutics stock.
DSGN Financial Performance
Revenues and expenses
DSGN Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Design Therapeutics stock?
Design Therapeutics (DSGN) has a market cap of $636M as of March 22, 2026.
What is the P/E ratio for Design Therapeutics stock?
The price to earnings (P/E) ratio for Design Therapeutics (DSGN) stock is 0 as of March 22, 2026.
Does Design Therapeutics stock pay dividends?
No, Design Therapeutics (DSGN) stock does not pay dividends to its shareholders as of March 22, 2026.
When is the next Design Therapeutics dividend payment date?
Design Therapeutics (DSGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Design Therapeutics?
Design Therapeutics (DSGN) has a beta rating of 1.63. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.